From the health system perspective, there needs to be improvement in treating HIV as a comprehensive disease that now goes into aging, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.
From the health system perspective, there needs to be improvement in treating HIV as a comprehensive disease that now goes into aging, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.
Transcript
With the advent of antiretroviral therapy, people living with HIV are living longer. With aging HIV populations, what challenges are there in treating patients with comorbidities, such as cancer?
I love my patient panel. I love seeing patients who, when they were in their early 20s and were diagnosed, thought they would be dead within years. Now they’re in their 50s and 60s and still going strong. One of the biggest challenges, I would say, comes from both a health system but also from the patients. From the health system perspective, I think we are still a little bit not so great about treating HIV as a comprehensive disease that now goes into aging.
From the patient perspective, I have patients who really believed they would be dead in a few years and so when you talk about things like other chronic disease management, like diabetes and smoking cessation, they have a feeling that their HIV is going to be the thing that impacts them anyway. So, there’s a little bit less of a sense of stopping some of the negative behaviors that have really been a problem for them. I think because of that, the behavioral change I do with some of these patients can be a little bit difficult.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More